Autolus Therapeutics (AUTL) Consolidated Net Income (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Consolidated Net Income for 9 consecutive years, with -$90.4 million the latest figure, recorded in Q4 2025.

• Quarterly Consolidated Net Income fell 227.32% year-over-year to -$90.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$287.6 million (down 30.32% YoY) and the FY2025 annual result came in at -$287.6 million, down 30.32% from the prior year.
• Consolidated Net Income fell to -$90.4 million in Q4 2025 per AUTL's latest filing, from -$79.1 million in the prior quarter.
• Over the last five years, Consolidated Net Income for AUTL reached as high as -$27.0 million in Q4 2022 and fell as low as -$90.4 million in Q4 2025.
• A 5-year average of -$50.4 million and a median of -$44.2 million in 2022 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2024 — Consolidated Net Income surged 64.23% — and 2025, when it slumped 227.32%.
• Year by year, Consolidated Net Income stood at -$41.7 million in 2021, then soared by 35.31% to -$27.0 million in 2022, then plunged by 186.04% to -$77.2 million in 2023, then jumped by 64.23% to -$27.6 million in 2024, then sank by 227.32% to -$90.4 million in 2025.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$90.4 million, -$79.1 million, and -$47.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.